Skip to main content

Table 2 Multivariate analysis of S100A8/A9, LDH, and M stage on progression-free survival in the pembrolizumab-treated patients (pembrolizumab set 2)

From: Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

 

Patients

 

No.

%

%

Prog.

HR

95% CI

p value

S100A8/A9

 ≤ 5.5 mg/l

39

88.6

48.7

1

  

 > 5.5 mg/l

5

11.4

100.0

10.1

2.72–37.6

.00055

LDH

 ≤ 2,5xULN

40

90.9

52.5

1

  

 > 2,5xULN

4

9.1

75.0

2.19

0.48–10.1

.31

M stage

 M0/M1a/b

14

31.8

57.1

1

  

 M1c

30

68.2

53.3

0.68

0.22–2.08

.50

  1. NOTE. Multivariate survival analysis included 44 patients of the pembrolizumab set 2. The model was adjusted for age and sex
  2. Abbreviations: CI confidence interval, HR hazard ratio, ICI immune checkpoint inhibitor, LDH lactate dehydrogenase, Prog. progression, ULN upper limit of normal